Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 616-995-5 | CAS number: 8018-01-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Administrative data
Description of key information
Based on effects in the nervous system, classification of mancozeb with STOT RE 2 is justified.
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
Additional information
The summary below is taken from the RAC Opinion proposing harmonised classification and labelling at EU level (March 2019) of Mancozeb.
The table below summarises findings related to neurotoxicity in the rat oral and inhalation studies including several studies which were negative with respect to neurotoxicity (however, negative studies with relatively low top doses have been omitted from the table). No specific signs of neurotoxicity were seen in the other three species tested (mouse, dog, rabbit) nor the in the rat dermal studies.
RAC notes that functional tests were probably not conducted in any of the available studies with the exception of the developmental neurotoxicity study by Anon. (2008c), which was negative. However, the top dose in this study was rather low (30 mg/kg bw/d).
Observations related to neurotoxicity in rat oral and inhalation repeated dose studies | |
Type of study; Reference | Observations related to neurotoxicity |
28-day gavage Anon. 1994b | 500 mg/kg bw/d: 1/6 females hind limb paralysis and killed for humane reasons on day 21; 2/6 females hind limb paralysis on day 28 200 mg/kg bw/d: 1/8 females ataxia and killed for humane reasons on day 13; 2/8 females ataxia 50 mg/kg bw/d: no effects |
12-week dietary (males only) Szépvölgyi et al. 1989 | 379 mg/kg bw/d: mortality 4/12 week 1-6; clinical signs: prostration, weakness and posterior distal paralysis before death of the 4 animals; signs were transient in survivors and absent at 12 weeks 253 mg/kg bw/d: no neurotoxicity-related findings |
90-day gavage Anon. 1999c | 400 mg/kg bw/d: mortality 2/24; no neurotoxicity-related findings |
90-day neurotoxicity, dietary Anon. 1991e | 339/413 mg/kg bw/d (m/f): Mortality: 1/10 males and 4/10 females weeks 2-4; treatment of females discontinued from day 15; large reductions in food consumption and bw loss in initial females during the first 2 weeks Clinical signs: abnormal gait and/or limited or no use of hind limbs (all animals, from week 2-3, some improvement by day 60), general weakness Histopathology: demyelination and Schwann cell proliferation in males and females; posterior thigh muscle atrophy (10/16 females)
50/63 mg/kg bw/d (m/f): No clinical signs of toxicity Histopathology: demyelination, Schwann cell proliferation (incidences provided in a separate table below)
8.2/10.5 mg/kg bw/d (m/f): no effects |
90-day dietary Anon. 1986b | 57/75 mg/kg bw/d: no neurotoxicity-related findings |
Prenatal developmental toxicity, gavage, dosing GD 6-15 Anon. 1980 | 512 mg/kg bw/d: 1/22 died, 2/22 killed after abortion; clinical signs: lethargy, ataxia, scruffy coat, diarrhoea or soft faeces, hunched, dehydrated |
Prenatal developmental toxicity, gavage, dosing GD 6-15 Anon. 1988c | 360 mg/kg bw/d: 1/25 killed in extremis, preceded by clinical sings (marked body weight loss, hind limb paralysis); further 4/25 slight, transient hind limb paralysis at the end of the dosing period |
2-week gavage (females only) Anon. 2015b | 300 mg/kg bw/d: no clinical signs of toxicity |
Prenatal developmental toxicity, gavage, dosing GD 6-19 Anon. 2015d | 160 mg/kg bw/d: no clinical signs of toxicity |
Developmental neurotoxicity, gavage, dosing GD 7 – PND 16 Axelstad et al. 2011 | Range-finding study: 500, 350 and 200 mg/kg bw/d: severe weight loss and hind limb paralysis in all groups by GD 12 (severity was dose-dependent), most dams sacrificed on GD 14 Main study: 150 mg/kg bw/d: severe weight loss, mild hind limb paralysis |
Prenatal developmental toxicity, inhalation, GD 6-15 Lu and Kennedy 1986 | 0.89 mg/L: mortality 30/37; hind limb weakness 11 animals (mild to moderate) 0.11 mg/L: mortality 3/37; hind limb weakness 24/37 (mild; onset after 7 exposures, persisted for 3 days after the last exposure) 0.055 mg/L: hind limb weakness 6/27 (mild) |
90-day inhalation Anon. 1986d | 0.33 mg/L: no clinical signs of toxicity |
The following table shows incidences of the histopathological findings at the mid-dose in the 90-day dietary neurotoxicity study Anon. (1991e).
Incidences of histopathological findings in the 90-day neurotoxicity study Anon. (1991e) at 750 ppm (50/63 mg/kg bw/d) | ||
| Males | Females |
Number of animals examined | 10 | 10 |
Cervical, dorsal root ganglion sections: Myelin bubbles Myelin phagocytosis Schwann cell proliferation |
1 1 1 |
1 |
Lumbar, dorsal root sections: Myelin bubbles* Myelin phagocytosis Schwann cell proliferation |
1 1 1 |
|
Lumbar, dorsal root ganglion sections: Myelin bubbles* Myelin phagocytosis Schwann cell proliferation |
2 1 1 |
|
Lumbar, ventral root sections: Myelin bubbles Myelin phagocytosis Schwann cell proliferation |
3 1 1 |
1 |
Tibial nerve, lower: Myelin bubbles Myelin phagocytosis Schwann cell proliferation | 2 2 |
|
* observed also in 1 control female
Clinical signs of neurotoxicity (hind limb weakness or paralysis, ataxia) were observed in several rat studies, in the oral studies mostly above 200 mg/kg bw/d, starting within the first few weeks of treatment. Demyelination and Schwann cell proliferation were identified as the histopathological correlate in the 90-day neurotoxicity study (Anon., 1991e) and appeared at a low incidence without clinical signs also at 50 mg/kg bw/d, which was below the GV for Category 2.
RAC considers the histopathological findings at the mid-dose in the 90-day neurotoxicity study sufficient for classification in Category 2, noting that similar damage may have occurred also in other rat studies without being detected due to lack of specific investigations (e.g., nerve fibre teasing). The clinical signs of neurotoxicity, although appearing mostly above the GVs, are considered to provide additional support for classification. Moreover, manganese, contained in mancozeb at a relatively high percentage, is an established neurotoxicant, and mancozeb itself has been shown to affect various neuronal cell populations in vitro (Domico et al., 2006), which further strengthens the case for classification.
ETU is most likely not the metabolite causing the neurotoxic effects, since ETU produced no evidence of neurotoxicity or developmental neurotoxicity in an extended one-generation reproduction toxicity study in rats, which included the cohort for developmental neurotoxicity (Anon., 2013).
Although neurotoxicity was only observed in the rat and not in the other species (the mouse and the dog), there is no information disproving human relevance of the rat findings. RAC notes that the mode of action of mancozeb-induced neurotoxicity is largely unknown.
Therefore, RAC agrees with the DS that classification of mancozeb with STOT RE 2 for effects on the nervous system is justified.
The consideration of other organs by RAC did not lead to proposed STOT RE classification and is discussed in the Background Document.
Route of exposure
According to the CLP regulation, the exposure route should be stated if it is conclusively proven that no other routes of exposure cause the hazard. As thyroid effects in the dog contributed to classification and no dog studies via the dermal and inhalation routes are available, effects warranting classification via those routes cannot be excluded in this species. In addition, neurotoxicity below the GVs was seen not only in oral studies but also after inhalation exposure in the rat (Lu and Kennedy, 1986). Hence, the conditions for specifying the exposure route are not fulfilled.
Justification for classification or non-classification
The overall conclusion on classification below is taken from the RAC Opinion proposing harmonised classification and labelling at EU level (March 2019) of Mancozeb.
RAC agrees with the DS that classification of mancozeb with STOT RE 2; H373 (thyroid; nervous system) is justified. This classification is based on reduced T4 levels in the dog and the rat and on neurotoxic findings in the rat. Mortality in the rat, the dog and the rabbit provides additional support for classification but in this case is not sufficient to trigger classification on its own. Contrary to the dossier submitter’s proposal, RAC does not consider it appropriate to specify the exposure route.
The registrant follows this conclusion.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.